DENOSUMAB (Ponlimisi®)

Clinical Indication

Osteoporosis

Comments

Full SCA

Biosimilar of denosumab; preferred first-line option in LLR for osteoporosis (60mg PFS).

 

Date of classification

February 2026

Orange

Shared Care Agreement. Higher risk medicines requiring significant regular monitoring which would be initiated by or at the recommendation of a specialist service which may include mental health services, secondary care, tertiary care, community providers, private providers and GPs with a specialist interest.